These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 32144992)

  • 1. Neurofilament Light Predicts Decline in Attention but Not Episodic Memory in Preclinical Alzheimer's Disease.
    Aschenbrenner AJ; Gordon BA; Fagan AM; Schindler SE; Balota DA; Morris JC; Hassenstab JJ
    J Alzheimers Dis; 2020; 74(4):1119-1129. PubMed ID: 32144992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.
    Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM;
    J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
    Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
    JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders.
    Olsson B; Portelius E; Cullen NC; Sandelius Å; Zetterberg H; Andreasson U; Höglund K; Irwin DJ; Grossman M; Weintraub D; Chen-Plotkin A; Wolk D; McCluskey L; Elman L; Shaw LM; Toledo JB; McBride J; Hernandez-Con P; Lee VM; Trojanowski JQ; Blennow K
    JAMA Neurol; 2019 Mar; 76(3):318-325. PubMed ID: 30508027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease.
    Gangishetti U; Christina Howell J; Perrin RJ; Louneva N; Watts KD; Kollhoff A; Grossman M; Wolk DA; Shaw LM; Morris JC; Trojanowski JQ; Fagan AM; Arnold SE; Hu WT
    Alzheimers Res Ther; 2018 Sep; 10(1):98. PubMed ID: 30253800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum.
    Bos I; Vos S; Verhey F; Scheltens P; Teunissen C; Engelborghs S; Sleegers K; Frisoni G; Blin O; Richardson JC; Bordet R; Tsolaki M; Popp J; Peyratout G; Martinez-Lage P; Tainta M; Lleó A; Johannsen P; Freund-Levi Y; Frölich L; Vandenberghe R; Westwood S; Dobricic V; Barkhof F; Legido-Quigley C; Bertram L; Lovestone S; Streffer J; Andreasson U; Blennow K; Zetterberg H; Visser PJ
    Alzheimers Dement; 2019 May; 15(5):644-654. PubMed ID: 30853464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between cerebrospinal fluid biomarkers of Alzheimer's disease and cognition in cognitively normal older adults.
    Pettigrew C; Soldan A; Moghekar A; Wang MC; Gross AL; O'Brien R; Albert M
    Neuropsychologia; 2015 Nov; 78():63-72. PubMed ID: 26394023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease.
    Benedet AL; Leuzy A; Pascoal TA; Ashton NJ; Mathotaarachchi S; Savard M; Therriault J; Kang MS; Chamoun M; Schöll M; Zimmer ER; Gauthier S; Labbe A; Zetterberg H; Rosa-Neto P; Blennow K;
    Brain; 2020 Dec; 143(12):3793-3804. PubMed ID: 33210117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subtle Differences in Cognition in 70-Year-Olds with Elevated Cerebrospinal Fluid Neurofilament Light and Neurogranin: A H70 Cross-Sectional Study.
    Rådestig MA; Skoog J; Zetterberg H; Skillbäck T; Zettergren A; Sterner TR; Fässberg MM; Sacuiu S; Waern M; Wetterberg H; Blennow K; Skoog I; Kern S
    J Alzheimers Dis; 2023; 91(1):291-303. PubMed ID: 36617786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
    J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study.
    de Wolf F; Ghanbari M; Licher S; McRae-McKee K; Gras L; Weverling GJ; Wermeling P; Sedaghat S; Ikram MK; Waziry R; Koudstaal W; Klap J; Kostense S; Hofman A; Anderson R; Goudsmit J; Ikram MA
    Brain; 2020 Apr; 143(4):1220-1232. PubMed ID: 32206776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias.
    Abu-Rumeileh S; Capellari S; Stanzani-Maserati M; Polischi B; Martinelli P; Caroppo P; Ladogana A; Parchi P
    Alzheimers Res Ther; 2018 Jan; 10(1):3. PubMed ID: 29368621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alzheimer's Disease Biomarkers and Future Decline in Cognitive Normal Older Adults.
    Dumurgier J; Hanseeuw BJ; Hatling FB; Judge KA; Schultz AP; Chhatwal JP; Blacker D; Sperling RA; Johnson KA; Hyman BT; Gómez-Isla T
    J Alzheimers Dis; 2017; 60(4):1451-1459. PubMed ID: 29036824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time Trends of Cerebrospinal Fluid Biomarkers of Neurodegeneration in Idiopathic Normal Pressure Hydrocephalus.
    Lukkarinen H; Tesseur I; Pemberton D; Van Der Ark P; Timmers M; Slemmon R; Janssens L; Streffer J; Van Nueten L; Bottelbergs A; Rauramaa T; Koivisto AM; Herukka SK; Korhonen VE; Junkkari A; Hiltunen M; Engelborghs S; Blennow K; Zetterberg H; Kolb HC; Leinonen V
    J Alzheimers Dis; 2021; 80(4):1629-1642. PubMed ID: 33720890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study.
    Lleó A; Alcolea D; Martínez-Lage P; Scheltens P; Parnetti L; Poirier J; Simonsen AH; Verbeek MM; Rosa-Neto P; Slot RER; Tainta M; Izaguirre A; Reijs BLR; Farotti L; Tsolaki M; Vandenbergue R; Freund-Levi Y; Verhey FRJ; Clarimón J; Fortea J; Frolich L; Santana I; Molinuevo JL; Lehmann S; Visser PJ; Teunissen CE; Zetterberg H; Blennow K
    Alzheimers Dement; 2019 Jun; 15(6):742-753. PubMed ID: 30967340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alzheimer's disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: Aβ
    Hampel H; Toschi N; Baldacci F; Zetterberg H; Blennow K; Kilimann I; Teipel SJ; Cavedo E; Melo Dos Santos A; Epelbaum S; Lamari F; Genthon R; Dubois B; Floris R; Garaci F; Lista S;
    Alzheimers Dement; 2018 Apr; 14(4):492-501. PubMed ID: 29328927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic accuracy of CSF neurofilament light chain protein in the biomarker-guided classification system for Alzheimer's disease.
    Lista S; Toschi N; Baldacci F; Zetterberg H; Blennow K; Kilimann I; Teipel SJ; Cavedo E; Dos Santos AM; Epelbaum S; Lamari F; Dubois B; Floris R; Garaci F; Hampel H;
    Neurochem Int; 2017 Sep; 108():355-360. PubMed ID: 28527630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Non-APOE Polygenic Risk Score for Alzheimer's Disease Is Associated With Cerebrospinal Fluid Neurofilament Light in a Representative Sample of Cognitively Unimpaired 70-Year Olds.
    Skoog I; Kern S; Najar J; Guerreiro R; Bras J; Waern M; Zetterberg H; Blennow K; Zettergren A
    J Gerontol A Biol Sci Med Sci; 2021 May; 76(6):983-990. PubMed ID: 33512503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
    Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
    J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study.
    Fagan AM; Henson RL; Li Y; Boerwinkle AH; Xiong C; Bateman RJ; Goate A; Ances BM; Doran E; Christian BT; Lai F; Rosas HD; Schupf N; Krinsky-McHale S; Silverman W; Lee JH; Klunk WE; Handen BL; Allegri RF; Chhatwal JP; Day GS; Graff-Radford NR; Jucker M; Levin J; Martins RN; Masters CL; Mori H; Mummery CJ; Niimi Y; Ringman JM; Salloway S; Schofield PR; Shoji M; Lott IT; ;
    Lancet Neurol; 2021 Aug; 20(8):615-626. PubMed ID: 34302786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.